tbuckley/cabot-search huggingface dataset:
OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND LEFT ATRIAL THROMBUS DESPITE CONTINUOUS NON-VITAMIN K ANTAGONIST ANTICOAGULANT AND WARFARIN THERAPY: INSIGHTS INTO RATES AND TIMING OF THROMBUS RESOLUTION
Authors: Jim W. Cheung, Salvatore A. D'Amato, Steven Markowitz, Christopher Liu, George Thomas, James E. Ip, Parmanand Singh, Bruce Lerman
Journal: Journal of the American College of Cardiology (2017)
INCIDENCE AND OUTCOMES OF PATIENTS REQUIRING SURGICAL BAIL-OUT DURING TRANSCATHETER AORTIC VALVE REPLACEMENT: A REPORT FROM THE NCDR® STS/ACC TRANSCATHETER VALVE THERAPY (TVT) REGISTRY
Authors: Andres M. Pineda Maldonado, J. Kevin Harrison, Neal Kleiman, Charanjit Rihal, Susheel Kodali, Ajay Kirtane, Martin Leon, Pratik Manandhar, Sreekanth Vemulapalli, Nirat Beohar
Journal: Journal of the American College of Cardiology (2017)
BACTERIAL ENDOCARDITIS IN A PATIENT WITH REPAIRED TETRALOGY OF FALLOT: A RARE CASE OF A HOMOGRAFT RIGHT VENTRICLE TO PULMONARY ARTERY CONDUIT ACUTE OBSTRUCTION
Authors: Shudhanshu Alishetti, Daniel Karlsberg, Nam Tran, Gary Milechman, Glenn Egrie
Journal: Journal of the American College of Cardiology (2017)
HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).
Authors: Frankie Ann Holmes, Corinne Ramos, Nicholas N Hoke, Maren K. Levin, Virginia A. Espina, Lance A. Liotta, Kai Wang, Norma Alonzo Palma, Joyce O'Shaughnessy
Journal: Journal of Clinical Oncology (2015)

621 Background: Pretreatment (preRx) biopsies of HER2-amplified breast cancers (BCs) that did not achieve pCR with preop chemotherapy plus H vs L vs HL had PI3K pathway activation with high p-FOXO levels on RPMA (Holmes BMC Res Notes 2013). The RD obtained at surgery in these pts was enriched for co-mutations in PIK3CA and TP53 (Holmes ASCO 2014, 625). Here we describe activated phosphoproteins in the HER1/2/3 pathway in the RD from these pts who did not achieve pCR with preop H vs L vs HL and in RD with PIK3CA/TP53 co-mutations. Methods: 15 pts’ FFPE RD BCs were acceptable for RPMA at a CLIA-certified laboratory (Theranostics Health). Immunostaining with 14 antibodies was directed against HER1/2/3 pathway proteins. Spearman correlation (ρ, p value) and Mann-Whitney U tests (p value) were performed. Results: 7 of 15 RD BCs had PIK3CA/TP53 co-mutations. In the RD with co-mutant PIK3CA/TP53, the strongest Pearson correlations (r) were between HER3 and p-HER1 and each with p-mTOR, p-S6K, p-JAK2 and p-STAT3 (all r > 0.9) In preop L pts (n = 8), the strongest correlations in the RD were p-HER2 and HER3, p-HER2 and p-mTOR, p-HER1 and p-STAT3 , p-HER3 and p-STAT3 (all r > 0.8), and p-4EBP1 and p-JAK2 (r = 0.97). In preop H and HL pts (n = 7), the RD showed strong interactions between HER3 and p-HER1, p-HER2 and p-HER3, HER3 and p-S6K, p-HER1 and p-S6K and p-HER3 and p-JAK2 (all r > 0.9). Comparing L- vs H/HL-treated RD, L-treated RD had higher levels of p-Akt (p = 0.08), p-S6 (p = 0.08) and p-MEK1/2 (p = 0.02). PreRx biopsies from pts who had RD all expressed high PI3K or low PTEN ser380 levels and showed strong interactions between p-HER1 and p-IGF1R, p-HER1, PI3K, and MAPK activation, LCB3 (autophagy) and PI3K, and Musashi (stem cell regulator) and β-catenin (all ρ > 0.8) (all p < 0.00006). Conclusions: PreRx biopsies from HER2+ pts who had RD following preop chemotherapy + H, L or HL showed activation of HER1, PI3K and MAPK pathways. Pts’ refractory RD demonstrated HER3, PI3K and JAK2 pathway activation under the selective pressure of preop H, L or HL. PIK3CA/TP53 co-mutated RD demonstrated signaling via p-HER1/HER3 to p-mTOR/p-S6K and p-JAK2/p-STAT3.
Evaluation of the toxicity and efficacy of paclitaxel nanoencapsulated with polyethyloxazoline polymers.
Authors: Ray Yin, Jing Pan, Bingsen Zhou, Yubei Zhang, Jeffrey Dougherty, Joanna Liu, Tracy A Riesenberger, Dujie Qin, Yli Remo Vallejo
Journal: Journal of Clinical Oncology (2013)

e13538 Background: Paclitaxel’s antineoplastic activity is limited by its solubility and toxicity. Encapsulation with polyethyloxazoline (PEOX) branched polymers can increase its solubility, decrease toxicity and enhance its antitumor efficacy. Methods: Paclitaxel was mixed with PEOX-based branched polymers at drug loading percentages of 11 - 17% to form nanoparticles (&lt; 90 nm in diameter). The product was purified and lyophilized as a white powder, designated FID-007. Its cytotoxicity was tested on normal human fibroblast cells and cell lines for human lung (A549), triple negative breast (MDA-MB-231) and ovarian (OV-90) cancers. Commercial paclitaxel drugs, Taxol and Abraxane, were similarly tested. Maximum tolerated dose (MTD) of the three drugs were determined in CD-1 mice. FID-007’s efficacy in controlling tumor growth was compared to the other drugs in vivo using xenograft tumor models in Scid mice with the three human cancer cell lines (20 mice per cancer). Saline and polymer were used as negative control treatments. Results: FID-007, Taxol and Abraxane showed similar cytotoxicity to all cancers.FID-007 was &gt; 10-fold less active in normal fibroblasts. The single dose MTD in CD-1 mice was &lt; 30 mg/kg for Taxol, 175 mg/kg for FID-007 and &gt;180 mg/kg for Abraxane. FID-007 exhibited the best efficacy in controlling tumor growth in mice compared to Taxol and Abraxane with the three human cancers. Results from the lung tumor study are presented in the Table. Conclusions: Encapsulation with PEOX-based polymers reduced the toxicity and significantly improved the efficacy of paclitaxel in controlling tumor growth in vitro and in vivo. [Table: see text]
TRATAMIENTO ENDOSCÓPICO DE DIVERTICULO DE ZENKER CON LIGASURE. RESULTADOS DE UN ESTUDIO MULTICENTRICO
Authors: E Brullet Benedí, D Juzgado, F González-Huix, MP Diez Redondo, E Vázquez Sequeiros, F Igea, C Dolz, F Vida, M Pérez Miranda, M Papo, R Campo
Journal: Endoscopy (2015)

Introducción: El tratamiento endoscópico del divertículo de Zenker (DZ) es una alternativa terapéutica menos invasiva que la cirugía convencional.
Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Authors: Michael F. Press, Peter H. O'Donnell, Elizabeth R. Plimack, Jean H. Hoffman-Censits, David I. Quinn, Padmanee Sharma, Todd DeVries, Melissa Chen, Michael Locker, Dean F. Bajorin
Journal: Journal of Clinical Oncology (2013)

4527^ Background: HER2 overexpression may be a prognostic factor for poor outcomes in pts with high-risk UC. Publications report a wide variability of HER2 expression in UC, with ≥2+ HER2 expression by immunohistochemistry (IHC) reported in &lt;10% to &gt;50% of cases. DN24-02 is an investigational autologous immunotherapy targeting HER2, based on the same manufacturing platform used for sipuleucel-T. NeuACT (N10-1; NCT01353222) is designed to evaluate whether DN24-02 can prolong survival when given as adjuvant therapy following surgical resection in pts with high risk HER2-expressing UC (Bajorin, et al. ASCO 2012). Here we report preliminary data for HER2 expression on primary tumor and positive lymph node samples, and covariate analyses. Methods: Trial eligibility criteria include surgical resection of a primary UC, with either ≥pT2 or pN+ staging, and HER2 expression ≥1+ IHC. Surgical specimens are screened for HER2 expression by central pathology laboratory review and HER2 positivity is scored using the Dako HercepTest system. Results: As of December 2012, tumor specimens from 114 pts have been screened. Of these pts, 84 (74%; 95% CI: 65–82%) had a HER2 expression score ≥1+ in the primary tumor, with 36 (32%) having a 2+ score and 5 (4%) having a 3+ score. Thirty-eight pts also had HER2 expression levels evaluated in lymph node samples. Of these 38 pts, 35 (92%; 95% CI: 79–98%) had a HER2 expression score ≥1+ in the lymph nodes, with 17 (45%) having a 2+ score and 4 (11%) having a 3+ score. Gender, primary tumor site, nodal stage and prior neoadjuvant chemotherapy were not significantly correlated with HER2 expression (p≥0.10). Conclusions: To date, high frequencies (≥74%) of HER2 expression ≥1+ in primary tumor and lymph node samples of UC pts have been observed. No baseline variables, including prior neoadjuvant chemotherapy, appear to affect the rate of HER2 expression. Although preliminary, these data are consistent with prior studies that have noted a higher incidence of HER2 expression in UC lymph node tumor vs. primary tumor and suggest that HER2 protein expression is common in high-risk UC. Clinical trial information: NCT01353222.
GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.
Authors: Dean Anthony Fennell, Glenwood D. Goss, Mark A. Socinski, Kazuhiko Nakagawa, Joan H. Schiller, Philip Bonomi, Vera Hirsh, Karen Kelly, James F. Spicer, Rafael Rosell, Bojan Zaric, Tudor-Eliade Ciuleanu, Vojislav M. Vukovic, Florentina Teofilovici, Iman El-Hariry, Wei Guo, Suresh S. Ramalingam
Journal: Journal of Clinical Oncology (2013)

TPS8126 Background: Hsp90 is a molecular chaperone recognized as a key facilitator of cancer cell growth and survival. Ganetespib is a resorcinolic Hsp90 inhibitor that has shown single-agent activity in patients with lung, breast, and other cancers after progression on standard treatments. Ganetespib in combination with docetaxel induces synergistic efficacy in human non-small-cell lung carcinoma (NSCLC) tumor xenografts. Ganetespib is well tolerated and has not shown severe liver or common ocular toxicities reported for other Hsp90 inhibitors. Transient diarrhea is the most common adverse event, and is manageable with appropriate supportive care. A large randomized study of ganetespib in combination with docetaxel in advanced NSCLC patients (GALAXY-1 Trial) is ongoing. Preliminary results indicate good tolerability of the combination, and improvement in efficacy, including OS. Methods: GALAXY-2 is a randomized (1:1), international, open-label phase III study enrolling patients who received and progressed on one prior systemic therapy for advanced NSCLC of adenocarcinoma histology. Patients (N=500) are prospectively stratified for ECOG PS, total LDH, and best response to first-line therapy. The primary endpoint is OS. Key secondary endpoints include: OS in 3 subpopulations (mKRAS and elevated LDH and LDH5); PFS, ORR, DCR, DOT, and DOR. Patients in the control arm are treated with docetaxel 75 mg/m 2 on Day 1 of a 3-week cycle. In the combination arm, ganetespib 150 mg/m 2 is given on Day 1 with 75 mg/m 2 docetaxel, and ganetespib 150 mg/m 2 alone is given on Day 15 of each 3-week cycle. Two interim analyses for OS will be performed. Tumor tissue and blood samples will be collected for planned translational studies.
DIFFERENCE IN QUALITY OF LIFE OUTCOMES BETWEEN ATRIAL FIBRILLATION CATHETER ABLATION AND ANTI ARRHYTHMIC DRUGS: A SYSTEMATIC REVIEW AND META ANALYSIS
Authors: Parikshit S. Sharma, Sampath Gunda, Santosh Padala, Samir Pancholy, Kenneth Ellenbogen
Journal: Journal of the American College of Cardiology (2017)
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
Authors: Darius Juskevicius, David Jucker, Dirk Klingbiel, Christoph Mamot, Stephan Dirnhofer, Alexandar Tzankov
Journal: Journal of Hematology & Oncology (2017)

Recently, the mutational background of diffuse large B cell lymphoma (DLBCL) has been revealed, identifying specific genetic events that drive lymphomagenesis. However, the prognostic value of these mutations remains to be determined. Prognostic biomarkers in DLBCL are urgently needed, since the current clinical parameter-based factors (e.g., International Prognostic Index (IPI)) are insufficient, particularly in identifying patients with poor prognosis who might benefit from alternative treatments. We investigated the prognostic value of somatic mutations in DLBCL in a clinical trial (NCT00544219) patient cohort homogenously treated with six cycles of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP), followed by two cycles of R (R-CHOP-14). The primary endpoint was event-free survival (EFS) at 2 years. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Targeted high-throughput sequencing (HTS) of tumor genomic DNA was performed on all exons or hotspots of 68 genes frequently mutated in B cell lymphomas. Mutational data was correlated with the endpoints to identify prognostic associations. Targeted HTS detected somatic mutations in 71/76 (93%) of investigated cases. The most frequently mutated genes were KMT2D, SOCS1, GNA13, and B2M. Survival analysis revealed that CREBBP- and EP300-mutated cases had significantly worse OS, PFS, and EFS. In addition, ATM mutations predicted worse outcomes for all three clinical endpoints in germinal center B cell-like DLBCL. In contrast, SOCS1 mutations were associated with better PFS. On multivariable analysis taken into account IPI and failure to achieve complete remission, CREBBP and EP300 mutations remained significant to predict worse OS, PFS, and EFS. Targeted mutation analysis of a uniformly treated prospective clinical trial DLBCL cohort identifies tumor-based genetic prognostic markers that could be useful in the clinical management of such patients. ClinicalTrials.gov NCT00544219
REAL WORLD BATTERY LONGEVITY OF ST. JUDE MEDICAL IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS INCLUDED IN THE ADVISORY FOR PREMATURE BATTERY DEPLETION
Authors: Madhu Reddy, Venkat Vuddanda, Mohammad-Ali Jazayeri, Madhav Lavu, Mohit Turagam, Bhavya Yarlagadda, Himadindu Korra, Rakesh Venkata, Vidhya Reddy, Martin Emert, Rhea Pimentel, Raghuveer Dendi, Seth Sheldon, Sudharani Bommana, Donita Atkins, Loren Berenbom, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
USEFULNESS OF OPTICAL COHERENCE TOMOGRAPHY-DERIVED MORPHOMETRIC ASSESSMENT TO PREDICT PHYSIOLOGICAL SIGNIFICANCE OF CORONARY ARTERY STENOSIS AND DETERMINANTS OF MISMATCH: HEAD-TO-HEAD COMPARISON WITH INTRAVASCULAR ULTRASOUND
Authors: Eisuke Usui, Taishi Yonetsu, Tetsumin Lee, Tadashi Murai, Yoshihisa Kanaji, Masahiro Hoshino, Takayuki Niida, Masahiro Hada, Rikuta Hamaya, Mitsuaki Isobe, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
PREDICTORS OF HIGH INTENSITY STATIN USE AFTER PERCUTANEOUS CORONARY INTERVENTIONS
Authors: Michela Faggioni, Zhen Ge, Samantha Sartori, Usman Baber, Annapoorna Kini, George Dangas, Sonny Sayseng, Jaya Chandrasekhar, Jason Kovacic, Pedro Moreno, Birgit Vogel, Serdar Farhan, Clayton Snyder, Joseph Sweeny, Sabato Sorrentino, Srinivas Kesanakurthy, Javed Suleman, Vishal Kapur, Nitin Barman, Choudhury Hasan, Roxana Mehran, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with <i>BRCA </i>mutations (<i>BRCA</i>+): A multicenter, prospective study.
Authors: Catherine A. Shu, Malcolm C. Pike, Anjali R. Jotwani, Tara M. Friebel, Robert A. Soslow, Douglas A. Levine, Mark E. Robson, Jason A. Konner, Joanne Lorraine Blum, Susan L. Neuhausen, Judy Ellen Garber, Mary Beryl Daly, Claudine Isaacs, Ros A. Eeles, Patricia A. Ganz, Carol Aghajanian, Kenneth Offit, Susan M. Domchek, Timothy R. Rebbeck, Noah D. Kauff
Journal: Journal of Clinical Oncology (2015)

1504 Background: While RRSO is key in management for BRCA+ women, concomitant hysterectomy is not standard. Here we estimate the risk of Ut Ca in BRCA+ women following RRSO and examine the distribution of specific histologic subtypes. Methods: BRCA+ women from 9 centers who underwent RRSO with retention of the uterus were prospectively followed from latest of ascertainment, BRCA testing, or RRSO. Censoring occurred at hysterectomy, Ut Ca diagnosis, last follow-up or death. Expected cancer incidence was determined using age and race specific SEER data, adjusted for prevalence of hysterectomy. Ut Ca were categorized into endometrioid endometrial cancer (E-EC) [e.g. endometrioid, adenocarcinoma NOS], serous endometrial cancer (S-EC) [e.g. serous, undifferentiated], and sarcoma. The observed-to-expected (Obs/Exp) ratios and lower limit of 97.5% CI were analyzed using 1-sided Poisson distribution test. Results: 1083 BRCA+ women were followed for a median 5.2 years. 8 incident Ut Ca were observed [4.2 Exp; Obs/Exp = 1.9, p = 0.06]. When stratified by subtype, there was no increased risk of E-EC [2 Obs vs 3.7 Exp; p = 0.29] or sarcoma [1 Obs vs 0.14 Exp; p = 0.13]. 5 S-EC were observed 7.2 – 12.9 yrs after RRSO [0.33 Exp; Obs/Exp = 15.2, p < 0.0001]. Tumor tissue was available from 4 BRCA1+ women. LOH and/or IHC analyses confirmed loss of BRCA1 function in 3 of 3 S-EC. In the sarcoma, BRCA1 function was retained. Analyses for S-EC stratified by prior breast cancer or tamoxifen use are below. Conclusions: While the overall risk of Ut Ca following RRSO does not appear to be increased, there is a small absolute increased risk of more aggressive S-EC (≈ 1.1% at 10 yrs in BRCA1+ women). Further studies are needed to define the risk/benefit of hysterectomy at time of RRSO. Obs/Exp Rates for S-EC Exp Obs F/U (Women-Yrs) Obs/Exp 1p* Lower 97.5% CI* of Obs/Exp All (n=1083) 0.33 5 6385 15.2 < 0.0001 4.9 BRCA1 (627) 0.18 4 3790 22.6 < 0.0001 6.2 BRCA2 (453) 0.15 1 2580 6.5 0.14 0.2 Br Ca Y (727) 0.25 4 4435 15.9 0.0001 4.4 N (356) 0.08 1 1950 12.7 0.08 0.3 Tam Y (273) 0.12 3 1879 24.8 0.0003 5.1 N (810) 0.21 2 4506 9.5 0.02 1.2 *1-sided values are reported because with small expected values, the Poisson distribution is markedly skewed.
Tumor genomic mutation profiling of germ cell tumors using “Profile”.
Authors: Elizabeth O'Donnell, Hope Feldman, Carlos Lago-Hernandez, Michelle S. Hirsch, Clair Beard, Eliezer Mendel Van Allen, Philip W. Kantoff, Christopher Sweeney
Journal: Journal of Clinical Oncology (2014)

4516 Background: Malignant germ cell tumors (GCTs) are the most common solid malignancy affecting males between the ages of 15 and 35. To date, little is known about the genomic landscape of GCTs. Methods: We used “Profile”, an enterprise-wide mutation detection protocol. OncoMap, the platform used for this work detects 471 mutations in 41 well characterized oncogenes in formalin-fixed paraffin-embedded (FFPE) tissue samples including KIT, KRAS and BRAF which have previously been described in GCT. After informed consent, tumor DNA isolation from 33 unique patients, and a battery of quality assurance tests, the samples were run on the OncoMap platform. Results: 33% (11/33) tumor samples harbored mutations. 9/11 were orchiectomy specimens from newly diagnosed patients and 2/11 were samples from metastatic disease sites in relapsed disease. One mutation was noted in each of the 11 samples. Somatic oncogene mutations were found in NRAS (4), KIT (3), MET (2), KRAS (1), and p53 (1). 9/16 seminoma specimens had mutations (8 cured with orchiectomy, 2 cured with radiation therapy, and 6 cured with chemotherapy). 2/17 non-seminoma GCT pts had metastatic disease and mutations and both were cured with chemotherapy. Conclusions: Genomic analysis of tumor DNA extracted from FFPE orchiectomy specimen is feasible and may provide novel insights into GCT biology. Sequenom analysis using OncoMap details presence of genetic mutations in some GCT pts and supports the feasibility and rationale for further analysis (more samples and sequencing).
Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.
Authors: John H. Strickler, Shannon McCall, Andrew B. Nixon, Herbert Pang, Christel Rushing, Christy Arrowood, Sherri Haley, Kellen Meadows, Herbert Hurwitz
Journal: Journal of Clinical Oncology (2013)

11036 Background: Src inhibition may augment sensitivity to chemotherapy, but in unselected patients (pts) with advanced solid tumors, src inhibitors have shown limited clinical activity. Biomarkers to predict benefit from src inhibitors in advanced solid tumors are not yet known. Methods: 22 pts (dose escalation cohort= 12 pts; colorectal cancer [CRC] expansion cohort= 10 pts) were enrolled in a phase I study to determine the safety and tolerability of the src inhibitor dasatinib with capecitabine, oxaliplatin, and bevacizumab (J Clin Oncol 29: 2011 [suppl; abstr 3586]). Src activation (src-a) was assessed in tumors from 16 evaluable pts. Src-a was measured by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded tumor samples using an antibody that selectively recognizes the active conformation of src (clone 28). A GI pathologist who was blinded to pt outcomes graded membranous src-a using a standard semi-quantitative method. The endpoint of this exploratory analysis was objective response rate ([ORR]= PR+CR). 2-sided Fisher’s Exact test was used to evaluate the association between ORR and src-a. Results: Across all tumor types, 8 tumors had no/faint src-a (IHC=0/1); 8 tumors had moderate/strong src-a (IHC≥2). Benign colonic epithelium had no src-a (IHC=0). The ORR was 75% (6/8) for pts with moderate/strong src-a versus (vs) 0% (0/8) for pts with no/faint src-a (p =0.007). In the CRC expansion cohort, the ORR was 83% (5/6) for patients with moderate/strong src-a vs 0% (0/2) for pts with no/faint src-a (p=0.107); progression free survival range was 7.9-24.4 months for pts with moderate/strong src-a. Conclusions: In this small phase I study, src-a is associated with benefit from the combination of dasatinib and oxaliplatin-based chemotherapy. Further evaluation of dasatinib in patients whose tumors demonstrate high levels of src-a may be warranted. Clinical trial information: NCT00920868.
Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice
Authors: Darja Karpova, Michael P. Rettig, Linda Eissenberg, Julie Ritchey, Matthew Holt, Richard Heier, Stacy Arnett, Marvin Meyers, David W. Griggs, Peter Ruminski, Dwight Morrow, John F DiPersio
Journal: Blood (2016)